Theradiag SA
PAR:ALTER

Watchlist Manager
Theradiag SA Logo
Theradiag SA
PAR:ALTER
Watchlist
Price: 1.26 EUR Market Closed
Market Cap: 16.4m EUR

Net Margin

3.3%
Current
Improving
by 3.7%
vs 3-y average of -0.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3.3%
=
Net Income
€420k
/
Revenue
€12.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
3.3%
=
Net Income
€420k
/
Revenue
€12.6m

Peer Comparison

Country Company Market Cap Net
Margin
FR
Theradiag SA
PAR:ALTER
16.4m EUR
Loading...
US
Abbott Laboratories
NYSE:ABT
211.7B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
191.8B USD
Loading...
US
Stryker Corp
NYSE:SYK
139.1B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
130.5B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
124B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
51.7B EUR
Loading...
US
Becton Dickinson and Co
NYSE:BDX
59.1B USD
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
57.2B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
49B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.6B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in France
Percentile
47th
Based on 1 962 companies
47th percentile
3.3%
Low
-147 400% — 0.6%
Typical Range
0.6% — 8.7%
High
8.7% — 2 278.7%
Distribution Statistics
France
Min -147 400%
30th Percentile 0.6%
Median 3.9%
70th Percentile 8.7%
Max 2 278.7%

Theradiag SA
Glance View

Market Cap
16.4m EUR
Industry
Health Care

Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.

ALTER Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
3.3%
=
Net Income
€420k
/
Revenue
€12.6m
What is Theradiag SA's current Net Margin?

The current Net Margin for Theradiag SA is 3.3%, which is above its 3-year median of -0.3%.

How has Net Margin changed over time?

Over the last 3 years, Theradiag SA’s Net Margin has increased from -5.5% to 3.3%. During this period, it reached a low of -6.9% on Dec 31, 2021 and a high of 3.3% on Jul 30, 2023.

Back to Top